AB Science's Upcoming Virtual Conference Details
AB Science is excited to announce a virtual conference scheduled to take place soon, where the focus will be on the Phase 1 study of AB8939. This pivotal event will shed light on the progress and findings associated with the innovative treatment for acute myeloid leukemia (AML), which is often characterized by challenging genetic profiles.
Insights on the AB8939 and Venetoclax Treatment
The company has made significant strides in clinical research, particularly concerning the combination treatment of AB8939 with Venetoclax. Initial data suggests that the treatment is well tolerated, with a 100% disease control rate among the first three patients evaluated. These individuals, all of whom had refractory or relapsed AML with unfavorable genetic markers, have shown promising responses to the therapy.
Understanding the Mechanism of AB8939
AB8939 works by destabilizing microtubules essential for cell division, targeting cancer stem cells while preserving non-tumor stem cells. This dual action was particularly emphasized when discussing the initial treatment outcomes of patients who previously experienced limited success with standard therapies.
Details of the Virtual Conference
Set to occur on Thursday, October 16, the virtual conference will run from 2 PM to 3 PM CET. Esteemed experts in the field of AML will participate, providing crucial insights into the ongoing research and patient outcomes.
Featured Experts
The conference will feature prominent figures, including Prof. Nicholas J. Short, MD, who is known for his groundbreaking work in developmental therapeutics. He will be joined by Prof. Olivier Hermine, MD, PhD, and Emeritus Prof. Christian Auclair, PharmD, PhD, both of whom bring extensive experience in hematology and cancer research.
Ongoing Phase 1 Clinical Trials
The Phase 1 clinical trial for AB8939 is currently progressing to a new stage that evaluates higher doses of the treatment. This phase aims to confirm the preliminary findings before proceeding to more extensive registration trials.
Future Directions for AB8939
In April 2025, AB Science achieved a significant milestone when AB8939 was granted orphan drug designation by the European Medicines Agency (EMA) for AML treatment. This designation marks an essential step towards making this innovative therapy more accessible to patients in need.
AB Science: A Brief Overview
Founded in 2001, AB Science is headquartered in Paris, France. The pharmaceutical company specializes in developing protein kinase inhibitors (PKIs) for serious medical conditions that lack effective treatments. With a robust pipeline, AB Science strives to address significant unmet medical needs.
Contact Information for AB Science
For further inquiries, AB Science's financial communication and media relations team can be reached via email at investors@ab-science.com.
Frequently Asked Questions
What is the focus of the upcoming virtual conference by AB Science?
The conference will focus on the Phase 1 study of AB8939 and its combination with Venetoclax for treating AML.
When is the virtual conference scheduled to take place?
The virtual conference will be held on Thursday, October 16, from 2 PM to 3 PM CET.
Who are the key speakers at the conference?
Key speakers include esteemed experts such as Prof. Nicholas J. Short, Prof. Olivier Hermine, and Prof. Christian Auclair.
What are the results from the initial data on AB8939?
The early results show a 100% disease control rate and a positive response in patients with challenging genetic profiles.
What is the significance of AB8939's orphan drug designation?
The orphan drug designation allows for expedited development processes and potential market exclusivity for AB8939 in treating AML.
